GlassScriptPhysician profile
Lucas Lindsell
NPI 1841235959
$141,758.83
in general payments reported to CMS, 2019-2025
24 companies · $54K in 2025
The $54K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $446 · 2021: $575 · 2022: $7,676 · 2023: $18K · 2024: $60K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,020 · Food and Beverage: $7,982 · Travel and Lodging: $7,104 · Consulting Fee: $5,895 · Honoraria: $5,140 · Entertainment: $130 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,736.59 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,020.00 |
| Food and Beverage | $7,982.48 |
| Travel and Lodging | $7,104.27 |
| Consulting Fee | $5,895.00 |
| Honoraria | $5,140.00 |
| Entertainment | $130.21 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $49,439.16 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $45,340.48 | 2022-2025 | Syfovre |
| Genentech USA, INC. | $25,922.27 | 2022-2025 | Susvimo, Vabysmo |
| Abbvie INC. | $9,585.94 | 2022-2025 | |
| Alimera Sciences, INC. | $3,871.57 | 2019-2024 | Iluvien, Yutiq |
| Genentech, INC. | $2,499.33 | 2019-2023 | Susvimo |
| Harrow Eye, LLC | $1,000.00 | 2025 | Triesence |
| Optos, INC. | $880.21 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $460.99 | 2022-2025 | Xipere, Miebo |
| Astellas Pharma US INC | $456.56 | 2023-2025 | Izervay |
| Eyepoint US, INC. | $391.27 | 2019-2022 | |
| Allergan, INC. | $371.96 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $298.34 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Alcon Vision LLC | $265.14 | 2019-2023 | Clareon |
| Dutch Ophthalmic, USA | $261.57 | 2024-2025 | Eva, Combined Machine, Tissueblue |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $138.46 | 2025 | Eylea Hd |
| Astellas US LLC | $135.72 | 2024 | Izervay |
| Carl Zeiss Meditec USA, INC. | $135.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $116.10 | 2019-2023 | |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Biogen, INC. | $54.60 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.12 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucas Lindsell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.